Nice
Recent ATHE News
- Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program • GlobeNewswire Inc. • 03/30/2026 11:25:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 10:03:09 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/19/2026 12:00:10 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/09/2026 12:00:00 PM
- Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit • GlobeNewswire Inc. • 03/09/2026 11:25:00 AM
- Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor • GlobeNewswire Inc. • 03/04/2026 12:25:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2026 11:03:24 AM
- Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments • GlobeNewswire Inc. • 03/02/2026 12:25:00 PM
- Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update • GlobeNewswire Inc. • 01/30/2026 12:25:00 PM
- Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 • GlobeNewswire Inc. • 01/21/2026 12:25:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2025 11:35:16 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2025 11:29:32 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2025 11:23:07 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2025 11:13:30 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2025 11:38:48 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/12/2025 01:08:15 PM
- Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference • GlobeNewswire Inc. • 11/12/2025 12:25:00 PM
- Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System • GlobeNewswire Inc. • 11/10/2025 12:25:00 PM
- Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report • GlobeNewswire Inc. • 10/31/2025 11:25:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/31/2025 11:12:43 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/21/2025 10:51:14 AM
- Alterity Therapeutics Shares Edge Higher After Encouraging MSA Trial Results • IH Market News • 10/09/2025 02:38:49 PM
- Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders • GlobeNewswire Inc. • 10/09/2025 11:25:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/09/2025 10:33:24 AM
- Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders • GlobeNewswire Inc. • 10/02/2025 11:35:00 AM
